TRAW has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
TRAW has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Traws Pharma has the Momentum Rank of 2.
Momentum Rank measures the strength and persistence of a stock's price movement over time, rated on a scale of 1 to 10.
For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.
Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.
For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.
A higher score reflects strong price momentum and indicates greater potential for superior performance. Conversely, a lower score indicates that momentum is either too high or too low, and stocks tend to underperform.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
For the Biotechnology subindustry, Traws Pharma's Momentum Rank, along with its competitors' market caps and Momentum Rank data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Traws Pharma's Momentum Rank distribution charts can be found below:
* The bar in red indicates where Traws Pharma's Momentum Rank falls into.
Thank you for viewing the detailed overview of Traws Pharma's Momentum Rank provided by GuruFocus.com. Please click on the following links to see related term pages.
Victor M Moyo | officer: CHIEF MEDICAL OFFICER | 12 PENNS TRAIL, NEWTOWN PA 18940 |
Trafford Clarke | director | 12 PENNS TRAIL, NEWTOWN PA 18940 |
Peter Atadja | director | 12 PENNS TRAIL, NEWTOWN PA 18940 |
Abraham N. Oler | officer: VP Corp Dev & Gen Counsel | C/O SPECTRUM PHARMACEUTICALS, 11500 SOUTH EASTERN AVENUE, SUITE 240, HENDERSON NV 89052 |
Steven M Fruchtman | officer: Chief Medical Officer | 375 PHEASANT RUN, NEWTOWN PA 18940 |
James J Marino | director | C/O ONCONOVA THERAPEUTICS, 375 PHEASANT RUN, NEWTOWN PA 18940 |
Gelder Mark S. Md | officer: Chief Medical Officer | C/O A.P. PHARMA, INC., 123 SAGINAW DRIVE, REDWOOD CITY CA 94063 |
Mark Patrick Guerin | officer: Chief Accounting Officer | 375 PHEASANT RUN, NEWTOWN PA 18940 |
Mary Teresa Shoemaker | director | 375 PHEASANT RUN, NEWTOWN PA 18940 |
Michael B Hoffman | director | 1 GREENWICH OFFICE PARK, GREENWICH CT 06831 |
E Premkumar Reddy | director | 375 PHEASANT RUN, NEWTOWN PA 18940 |
Jerome Groopman | director | C/O GENTA INC, TWO CONNELL DR, BERKELEY HEIGHTS NJ 07922 |
Viren Mehta | director | OSI PHARMACEUTICALS INC, 58 S SERVICE RD STE 110, MELVILLE NY 11747 |
Tyndall Capital Partners L P | 10 percent owner | 150 EAST 58TH STREET, 14TH FLOOR, NEW YORK NY 10155 |
Armistice Capital, Llc | 10 percent owner | 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022 |
From GuruFocus
By Marketwired • 08-14-2024
By Marketwired • 11-14-2024
By Marketwired • 05-23-2024
By Marketwired • 03-25-2025
By GuruFocus Research • 09-24-2024
By Marketwired • 08-15-2024
By GuruFocus News • 01-09-2025
By Marketwired • 02-28-2025
By Marketwired • 03-31-2025
By GuruFocus News • 01-30-2025
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.